
Gene Therapy R&D Market Report 2024-2034
Description
Gene Therapy R&D Market Report 2024-2034
The Gene Therapy R&D Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Gene Therapy Resurgence Fuelled by Groundbreaking Advancements, Soaring Investments, and a Promising Pipeline Reshaping Medicine's Future
In the past five years, gene therapy has made a remarkable comeback. Advancements in virology, vector and capsid architecture, and manufacturing have led to exciting breakthroughs and regulatory progress, capturing the attention of biotech investors. Biopharma firms are strategizing to gain an edge, expanding facilities, forming partnerships, and collaborating with contract manufacturing organizations (CMOs).
According to a recent report by the Alliance for Regenerative Medicine, over 1,400 global companies are focused on cell and gene therapies (CGTs), with 3,500 therapies in development and over 2,000 active clinical trials. North America leads in clinical trials, followed by the Asia Pacific and Europe, with oncology and rare diseases as the primary therapeutic targets. Venture capital remains the main driver of growth, reflecting enthusiasm for scientific advancements and potential treatment breakthroughs.
The FDA expects to receive over 200 investigational new drug applications for CGTs annually, approving 10 to 20 new therapies per year. In 2024, up to 21 cell therapy and 31 gene therapy launches are anticipated, prompting the FDA to elevate its Office of Tissues and Advanced Therapies (OTAT) within the Center for Biologics Research and Evaluation (CBER). Proposed structural changes aim to enhance review capabilities and expertise to accommodate the growing workload and ensure efficient regulatory processes.
What Questions Should You Ask before Buying a Market Research Report?
- How is the gene therapy R&D market evolving?
- What is driving and restraining the gene therapy R&D market?
- How will each gene therapy R&D submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
- How will the market shares for each gene therapy R&D submarket develop from 2024 to 2034?
- What will be the main driver for the overall market from 2024 to 2034?
- Will leading gene therapy R&D markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
- Who are the leading players and what are their prospects over the forecast period?
- What are the gene therapy R&D projects for these leading companies?
- How will the industry evolve during the period between 2024 and 2034? What are the implications of
gene therapy R&D projects taking place now and over the next 10 years? - Is there a greater need for product commercialisation to further scale the gene therapy R&D market?
- Where is the gene therapy R&D market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
- Our 340-page report provides 156 tables and 192 charts/graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them – NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
Forecasts to 2034 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.
Segments Covered in the Report
Disease
- Cancer
- Rare Diseases
- Oncologic
- Non-oncologic - Cardiovascular Diseases
- Ophthalmic Diseases
- Haematology
- Neurological
- Diabetes Mellitus
- Other Diseases
- Viral
- Retrovirus
- Adenovirus
- AAV
- Lentivirus
- Others - Non-viral
- Naked DNA
- Gene Gun
- Electroporation
- Lipofection
Techniques
- Gene Augmentation Therapy
- Gene Replacement Therapy
- Small/Medium Pharma & Biotech
- Universities & Research Institutes
- Hospitals
- Government & Public Bodies
- Big Pharma
North America
- U.S.
- Canada
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Brazil
- Mexico
- Rest of Latin America
- GCC
- South Africa
- Rest of MEA
Leading companies profiled in the report
- American Gene Technologies
- Applied Genetic
- Astellas Pharma Inc.
- Bayer
- Benitec BioPharma
- Biogen
- Bluebird Bio
- Bristol Myers Squibb
- Calimmune, Inc. (CSL Behiring)
- Cellectis
- GeneQuine Biotherapeutics
- GenSight Biologics
- Gilead Lifesciences, Inc.
- Novartis AG
- Ocugen, Inc.
- Orchard Therapeutics
- Oxford Biomedica
- Pfizer, Inc.
- REGENXBIO Inc.
- Sangamo Therapeutics, Inc.
- Sanofi
- Sarepta Therapeutics, Inc.
- Spark Therapeutics (Subsidiary of Roche)
- Takeda Pharmaceuticals
- Taysha GTx
- Transgene
- UniQure N. V.
- ViGeneron
- Voyager Therapeutics
How will the Gene Therapy R&D Market, 2024 to 2034 report help you?
In summary, our 340-page report provides you with the following knowledge:
- Revenue forecasts to 2034 for Gene Therapy R&D Market 2024 to 2034, with forecasts for disease, vector, techniques, and participants, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2034 for five regional and 22 key national markets – See forecasts for the Gene Therapy R&D Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market – including company profiles for 29 of the major companies involved in the Gene Therapy R&D Market, 2024 to 2034.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Gene Therapy R&D Market 2024 to 2034, market-leading companies. You will find data, trends and predictions.
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher..
The publisher is using a password system to access single user and team licenses. Single user (non-printable) and team licenses expire after 12 month period. In the case of team license purchases, the publisher requires all email addresses for the licensed users prior to fulfilment.
Table of Contents
340 Pages
- 1 Report Overview
- 1.1 Objectives of the Study
- 1.2 Introduction to Gene Therapy R&D Market
- 1.3 What This Report Delivers
- 1.4 Why You Should Read This Report
- 1.5 Key Questions Answered by This Analytical Report Include:
- 1.6 Who is This Report For?
- 1.7 Methodology
- 1.7.1 Market Definitions
- 1.7.2 Market Evaluation & Forecasting Methodology
- 1.7.3 Data Validation
- 1.7.3.1 Primary Research
- 1.7.3.2 Secondary Research
- 1.8 Frequently Asked Questions (FAQs)
- 1.9 Associated Visiongain Reports
- 1.10 About Visiongain
- 2 Executive Summary
- 3 Market Overview
- 3.1 Key Findings
- 3.2 Market Dynamics
- 3.2.1 Market Driving Factors
- 3.2.1.1 Robust Gene Therapy Pipeline to Boost Growth
- 3.2.1.2 Technological Advancements to Fuel Market Growth
- 3.2.1.3 Increasing Financing and Acquisitions by Major Players
- 3.2.1.4 Growing Prevalence of Targeted Diseases Treatment
- 3.2.2 Market Restraining Factors
- 3.2.2.1 Cell & Gene Therapies Target Specific Diseases
- 3.2.2.2 High Cost to Stifle Gene Therapy R&D Growth
- 3.2.2.3 Regulatory Scenarios to Challenge Industry Growth
- 3.2.3 Market Opportunities
- 3.2.3.1 Growing Number of Clinical Trials to Offer Lucrative Growth Opportunities
- 3.2.3.2 Facility Expansion Anticipated to Offer Lucrative Growth Prospects
- 3.2.3.3 Artificial Intelligence Can Bring Value to Gene Therapy R&D
- 3.3 COVID-19 Impact Analysis
- 3.4 Porter’s Five Forces Analysis
- 3.4.1 Bargaining Power of Suppliers
- 3.4.2 Bargaining Power of Buyers
- 3.4.3 Competitive Rivalry
- 3.4.4 Threat of Substitute Products
- 3.4.5 Threat of New Entrants
- 3.5 PEST Analysis
- 3.5.1 Political Factors Impacting Gene Therapy R&D Market
- 3.5.2 Economic Factors Impacting Gene Therapy R&D Market
- 3.5.3 Social Factors Impacting Gene Therapy R&D Market
- 3.5.4 Technological Factors Impacting Gene Therapy R&D Market
- 4 Gene Therapy R&D Market Analysis by Disease
- 4.1 Key Findings
- 4.2 Disease Segment: Market Attractiveness Index
- 4.3 Gene Therapy R&D Market Size Estimation and Forecast by Disease
- 4.4 Cancer
- 4.4.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
- 4.4.2 Market Share by Region, 2024 & 2034 (%)
- 4.5 Rare Diseases
- 4.5.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
- 4.5.2 Market Share by Region, 2024 & 2034 (%)
- 4.6 Cardiovascular Diseases
- 4.6.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
- 4.6.2 Market Share by Region, 2024 & 2034 (%)
- 4.7 Ophthalmic Diseases
- 4.7.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
- 4.7.2 Market Share by Region, 2024 & 2034 (%)
- 4.8 Hematology
- 4.8.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
- 4.8.2 Market Share by Region, 2024 & 2034 (%)
- 4.9 Neurological
- 4.9.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
- 4.9.2 Market Share by Region, 2024 & 2034 (%)
- 4.10 Diabetes Mellitus
- 4.10.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
- 4.10.2 Market Share by Region, 2024 & 2034 (%)
- 4.11 Other Diseases
- 4.11.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
- 4.11.2 Market Share by Region, 2024 & 2034 (%)
- 5 Gene Therapy R&D Market Analysis by Vector
- 5.1 Key Findings
- 5.2 Vector Segment: Market Attractiveness Index
- 5.3 Gene Therapy R&D Market Size Estimation and Forecast by Vector
- 5.4 Viral
- 5.4.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
- 5.4.2 Market Share by Region, 2024 & 2034 (%)
- 5.5 Non-viral
- 5.5.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
- 5.5.2 Market Share by Region, 2024 & 2034 (%)
- 6 Gene Therapy R&D Market Analysis by Techniques
- 6.1 Key Findings
- 6.2 Techniques Segment: Market Attractiveness Index
- 6.3 Gene Therapy R&D Market Size Estimation and Forecast by Techniques
- 6.4 Gene Augmentation Therapy
- 6.4.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
- 6.4.2 Market Share by Region, 2024 & 2034 (%)
- 6.5 Gene Replacement Therapy
- 6.5.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
- 6.5.2 Market Share by Region, 2024 & 2034 (%)
- 7 Gene Therapy R&D Market Analysis by Participants
- 7.1 Key Findings
- 7.2 Participants Segment: Market Attractiveness Index
- 7.3 Gene Therapy R&D Market Size Estimation and Forecast by Participants
- 7.4 Small/Medium Pharma & Biotech
- 7.4.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
- 7.4.2 Market Share by Region, 2024 & 2034 (%)
- 7.5 Universities & Research Institutes
- 7.5.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
- 7.5.2 Market Share by Region, 2024 & 2034 (%)
- 7.6 Hospitals, Government & Public Bodies
- 7.6.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
- 7.6.2 Market Share by Region, 2024 & 2034 (%)
- 7.7 Big Pharma
- 7.7.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
- 7.7.2 Market Share by Region, 2024 & 2034 (%)
- 8 Gene Therapy R&D Market Analysis by Region
- 8.1 Key Findings
- 8.2 Regional Market Size Estimation and Forecast
- 9 North America Gene Therapy R&D Market Analysis
- 9.1 Key Findings
- 9.2 North America Gene Therapy R&D Market Attractiveness Index
- 9.3 North America Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
- 9.4 North America Gene Therapy R&D Market Size Estimation and Forecast by Country
- 9.5 North America Gene Therapy R&D Market Size Estimation and Forecast by Disease
- 9.6 North America Gene Therapy R&D Market Size Estimation and Forecast by Vector
- 9.7 North America Gene Therapy R&D Market Size Estimation and Forecast by Techniques
- 9.8 North America Gene Therapy R&D Market Size Estimation and Forecast by Participants
- 9.9 U.S. Gene Therapy R&D Market Analysis
- 9.10 Canada Gene Therapy R&D Market Analysis
- 10 Europe Gene Therapy R&D Market Analysis
- 10.1 Key Findings
- 10.2 Europe Gene Therapy R&D Market Attractiveness Index
- 10.3 Europe Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
- 10.4 Europe Gene Therapy R&D Market Size Estimation and Forecast by Country
- 10.5 Europe Gene Therapy R&D Market Size Estimation and Forecast by Disease
- 10.6 Europe Gene Therapy R&D Market Size Estimation and Forecast by Vector
- 10.7 Europe Gene Therapy R&D Market Size Estimation and Forecast by Techniques
- 10.8 Europe Gene Therapy R&D Market Size Estimation and Forecast by Participants
- 10.9 Germany Gene Therapy R&D Market Analysis
- 10.10 UK Gene Therapy R&D Market Analysis
- 10.11 France Gene Therapy R&D Market Analysis
- 10.12 Italy Gene Therapy R&D Market Analysis
- 10.13 Spain Gene Therapy R&D Market Analysis
- 10.14 Russia Gene Therapy R&D Market Analysis
- 10.15 Rest of Europe Gene Therapy R&D Market Analysis
- 11 Asia Pacific Gene Therapy R&D Market Analysis
- 11.1 Key Findings
- 11.2 Asia Pacific Gene Therapy R&D Market Attractiveness Index
- 11.3 Asia Pacific Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
- 11.4 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Country
- 11.5 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Disease
- 11.6 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Vector
- 11.7 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Techniques
- 11.8 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Participants
- 11.9 Japan Gene Therapy R&D Market Analysis
- 11.10 China Gene Therapy R&D Market Analysis
- 11.11 India Gene Therapy R&D Market Analysis
- 11.12 Australia Gene Therapy R&D Market Analysis
- 11.13 South Korea Gene Therapy R&D Market Analysis
- 11.14 South East Asia Gene Therapy R&D Market Analysis
- 11.15 Rest of Asia Pacific Gene Therapy R&D Market Analysis
- 12 Latin America Gene Therapy R&D Market Analysis
- 12.1 Key Findings
- 12.2 Latin America Gene Therapy R&D Market Attractiveness Index
- 12.3 Latin America Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
- 12.4 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Country
- 12.5 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Disease
- 12.6 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Vector
- 12.7 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Techniques
- 12.8 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Participants
- 12.9 Brazil Gene Therapy R&D Market Analysis
- 12.10 Mexico Gene Therapy R&D Market Analysis
- 12.11 Rest of Latin America Gene Therapy R&D Market Analysis
- 13 MEA Gene Therapy R&D Market Analysis
- 13.1 Key Findings
- 13.2 MEA Gene Therapy R&D Market Attractiveness Index
- 13.3 MEA Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
- 13.4 MEA Gene Therapy R&D Market Size Estimation and Forecast by Country
- 13.5 MEA Gene Therapy R&D Market Size Estimation and Forecast by Disease
- 13.6 MEA Gene Therapy R&D Market Size Estimation and Forecast by Vector
- 13.7 MEA Gene Therapy R&D Market Size Estimation and Forecast by Techniques
- 13.8 MEA Gene Therapy R&D Market Size Estimation and Forecast by Participants
- 13.9 GCC Gene Therapy R&D Market Analysis
- 13.10 South Africa Gene Therapy R&D Market Analysis
- 13.11 Rest of MEA Gene Therapy R&D Market Analysis
- 14 Company Profiles
- 14.1 Astellas Pharma Inc.
- 14.1.1 Company Snapshot
- 14.1.2 Company Overview
- 14.1.3 Financial Analysis
- 14.1.3.1 Net Revenue, 2015-2023
- 14.1.3.2 Regional Market Shares, 2022
- 14.1.3.3 R&D, 2015-2023
- 14.1.4 Product Benchmarking
- 14.2 American Gene Technologies
- 14.2.1 Company Snapshot
- 14.2.2 Company Overview
- 14.2.3 Product Benchmarking
- 14.3 Beacon Therapeutics
- 14.3.1 Company Snapshot
- 14.3.2 Company Overview
- 14.3.3 Financial Analysis
- 14.3.3.1 Net Revenue, 2015-2022
- 14.3.3.2 R&D, 2015-2022
- 14.3.4 Product Benchmarking
- 14.3.5 Strategic Outlook
- 14.4 Bayer
- 14.4.1 Company Snapshot
- 14.4.2 Company Overview
- 14.4.3 Financial Analysis
- 14.4.3.1 Net Revenue, 2015-2023
- 14.4.3.2 Regional Market Shares, 2023
- 14.4.3.3 Business Segment Market Shares, 2023
- 14.4.3.4 R&D, 2015-2023
- 14.4.4 Product Benchmarking
- 14.4.5 Strategic Outlook
- 14.5 Benitec BioPharma
- 14.5.1 Company Snapshot
- 14.5.2 Company Overview
- 14.5.3 Financial Analysis
- 14.5.3.1 Net Revenue, 2015-2023
- 14.5.3.2 R&D, 2015-2023
- 14.5.4 Product Benchmarking
- 14.6 Biogen
- 14.6.1 Company Snapshot
- 14.6.2 Company Overview
- 14.6.3 Financial Analysis
- 14.6.3.1 Net Revenue, 2015-2023
- 14.6.3.2 Regional Market Shares, 2022
- 14.6.3.3 R&D, 2015-2023
- 14.6.4 Product Benchmarking
- 14.6.5 Strategic Outlook
- 14.7 Bluebird Bio
- 14.7.1 Company Snapshot
- 14.7.2 Company Overview
- 14.7.3 Financial Analysis
- 14.7.3.1 Net Revenue, 2015-2023
- 14.7.3.2 R&D, 2015-2023
- 14.7.4 Product Benchmarking
- 14.7.5 Strategic Outlook
- 14.8 Bristol Myers Squibb
- 14.8.1 Company Snapshot
- 14.8.2 Company Overview
- 14.8.3 Financial Analysis
- 14.8.3.1 Net Revenue, 2015-2023
- 14.8.3.2 Regional Market Shares, 2023
- 14.8.3.3 R&D, 2015-2023
- 14.8.4 Product Benchmarking
- 14.8.5 Strategic Outlook
- 14.9 Calimmune, Inc. (CSL Behiring)
- 14.9.1 Company Snapshot
- 14.9.2 Company Overview
- 14.9.3 Product Benchmarking
- 14.9.4 Strategic Outlook
- 14.10 Cellectis
- 14.10.1 Company Snapshot
- 14.10.2 Company Overview
- 14.10.3 Financial Analysis
- 14.10.3.1 Net Revenue, 2015-2023
- 14.10.3.2 R&D, 2015-2023
- 14.10.4 Product Benchmarking
- 14.10.5 Strategic Outlook
- 14.11 GenSight Biologics
- 14.11.1 Company Snapshot
- 14.11.2 Company Overview
- 14.11.3 Product Benchmarking
- 14.12 Gilead Lifesciences, Inc.
- 14.12.1 Company Snapshot
- 14.12.2 Company Overview
- 14.12.3 Financial Analysis
- 14.12.3.1 Net Revenue, 2015-2023
- 14.12.3.2 R&D, 2015-2023
- 14.12.4 Product Benchmarking
- 14.13 Novartis AG
- 14.13.1 Company Snapshot
- 14.13.2 Company Overview
- 14.13.3 Financial Analysis
- 14.13.3.1 Net Revenue, 2015-2023
- 14.13.3.2 Regional Market Shares, 2023
- 14.13.3.3 Business Segment Market Shares, 2023
- 14.13.3.4 R&D, 2015-2023
- 14.13.4 Product Benchmarking
- 14.13.5 Strategic Outlook
- 14.14 Orchard Therapeutics
- 14.14.1 Company Snapshot
- 14.14.2 Company Overview
- 14.14.3 Product Benchmarking
- 14.15 Oxford Biomedica
- 14.15.1 Company Snapshot
- 14.15.2 Company Overview
- 14.15.3 Financial Analysis
- 14.15.3.1 Net Revenue, 2015-2023
- 14.15.3.2 Regional Market Shares, 2023
- 14.15.4 Product Benchmarking
- 14.15.5 Strategic Outlook
- 14.16 Pfizer, Inc.
- 14.16.1 Company Snapshot
- 14.16.2 Company Overview
- 14.16.3 Financial Analysis
- 14.16.3.1 Net Revenue, 2015-2023
- 14.16.3.2 Regional Market Shares, 2023
- 14.16.3.3 Business Segment Market Shares, 2023
- 14.16.3.4 R&D, 2015-2023
- 14.16.4 Product Benchmarking
- 14.16.5 Strategic Outlook
- 14.17 REGENXBIO Inc.
- 14.17.1 Company Snapshot
- 14.17.2 Company Overview
- 14.17.3 Financial Analysis
- 14.17.3.1 Net Revenue, 2015-2023
- 14.17.3.2 R&D, 2015-2023
- 14.17.4 Product Benchmarking
- 14.17.5 Strategic Outlook
- 14.18 Sangamo Therapeutics, Inc.
- 14.18.1 Company Snapshot
- 14.18.2 Company Overview
- 14.18.3 Financial Analysis
- 14.18.3.1 Net Revenue, 2015-2023
- 14.18.3.2 R&D, 2015-2023
- 14.18.4 Product Benchmarking
- 14.18.5 Strategic Outlook
- 14.19 Sanofi
- 14.19.1 Company Snapshot
- 14.19.2 Company Overview
- 14.19.3 Financial Analysis
- 14.19.3.1 Net Revenue, 2015-2023
- 14.19.3.2 Regional Market Shares, 2023
- 14.19.3.3 R&D, 2015-2023
- 14.19.4 Product Benchmarking
- 14.19.5 Strategic Outlook
- 14.20 Spark Therapeutics (Subsidiary of Roche)
- 14.20.1 Company Snapshot
- 14.20.2 Company Overview
- 14.20.3 Product Benchmarking
- 14.20.4 Strategic Outlook
- 14.21 Takeda Pharmaceuticals
- 14.21.1 Company Snapshot
- 14.21.2 Company Overview
- 14.21.3 Financial Analysis
- 14.21.3.1 Net Revenue, 2015-2023
- 14.21.3.2 R&D, 2015-2023
- 14.21.4 Product Benchmarking
- 14.21.5 Strategic Outlook
- 14.22 Transgene
- 14.22.1 Company Snapshot
- 14.22.2 Company Overview
- 14.22.3 Product Benchmarking
- 14.23 UniQure NV
- 14.23.1 Company Snapshot
- 14.23.2 Company Overview
- 14.23.3 Financial Analysis
- 14.23.3.1 Net Revenue, 2015-2023
- 14.23.3.2 R&D, 2015-2023
- 14.23.4 Product Benchmarking
- 14.23.5 Strategic Outlook
- 14.24 Voyager Therapeutics
- 14.24.1 Company Snapshot
- 14.24.2 Company Overview
- 14.24.3 Financial Analysis
- 14.24.3.1 Net Revenue, 2015-2023
- 14.24.3.2 R&D, 2015-2023
- 14.24.4 Product Benchmarking
- 14.24.5 Strategic Outlook
- 14.25 ViGeneron
- 14.25.1 Company Snapshot
- 14.25.2 Company Overview
- 14.25.3 Product Benchmarking
- 14.25.4 Strategic Outlook
- 14.26 GQ Bio Therapeutics GmbH
- 14.26.1 Company Snapshot
- 14.26.2 Company Overview
- 14.26.3 Product Benchmarking
- 14.26.4 Strategic Outlook
- 14.27 OCUGEN, INC.
- 14.27.1 Company Snapshot
- 14.27.2 Company Overview
- 14.27.3 Product Benchmarking
- 14.27.4 Strategic Outlook
- 14.28 Taysha GTx
- 14.28.1 Company Snapshot
- 14.28.2 Company Overview
- 14.28.3 Product Benchmarking
- 14.29 Sarepta Therapeutics, Inc.
- 14.29.1 Company Snapshot
- 14.29.2 Company Overview
- 14.29.3 Product Benchmarking
- 14.29.4 Strategic Outlook
- 15 Conclusion and Recommendations
- 15.1 Concluding Remarks from Visiongain
- 15.2 Recommendations for Market Players
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.